This combination is a unique and powerful blend that targets multiple metabolic pathways. It combines the triple-agonist activity of retatrutide, which mimics GLP-1, GIP, and glucagon, with the amylin-mimicking effects of cagrilintide.
How this blend work :
Enhanced Appetite Suppression and Satiety: Retatrutide's GLP-1 and GIP agonism slows the gastric emptying and increase feelings of fullness. By the action of cagrilintide, which works on the central nervous system to reduce appetite and promote satiety. The combined effect would likely lead to a very strong reduction in food intake.
Comprehensive Blood Sugar Control: Retatrutide can improve insulin sensitivity and glucose uptake, while also suppressing glucagon, which raises blood sugar. Cagrilintide complement this by further slowing gastric emptying and helping to regulate post-meal blood sugar spikes. This offers a more robust approach to glycemic control.
Dual Mechanism on Fat Metabolism: The glucagon receptor agonism in retatrutide can increase energy expenditure and promote the breakdown of fat. Cagrilintide's effects on satiety would help reduce calorie intake, creating a favorable environment for weight loss. The blend, in research, both increase the body's energy "out" and decrease the energy "in."
Potential Synergistic Weight Loss: By hitting multiple targets (appetite, satiety, energy expenditure, and glucose metabolism) from different angles, the combination research has led to lead to more significant and sustained weight loss than either drug alone. The sum of their individual effects might be greater than the parts, as they could reinforce each other's mechanisms.
This combination is a unique and powerful blend that targets multiple metabolic pathways. It combines the triple-agonist activity of retatrutide, which mimics GLP-1, GIP, and glucagon, with the amylin-mimicking effects of cagrilintide.
How this blend work :
Enhanced Appetite Suppression and Satiety: Retatrutide's GLP-1 and GIP agonism slows the gastric emptying and increase feelings of fullness. By the action of cagrilintide, which works on the central nervous system to reduce appetite and promote satiety. The combined effect would likely lead to a very strong reduction in food intake.
Comprehensive Blood Sugar Control: Retatrutide can improve insulin sensitivity and glucose uptake, while also suppressing glucagon, which raises blood sugar. Cagrilintide complement this by further slowing gastric emptying and helping to regulate post-meal blood sugar spikes. This offers a more robust approach to glycemic control.
Dual Mechanism on Fat Metabolism: The glucagon receptor agonism in retatrutide can increase energy expenditure and promote the breakdown of fat. Cagrilintide's effects on satiety would help reduce calorie intake, creating a favorable environment for weight loss. The blend, in research, both increase the body's energy "out" and decrease the energy "in."
Potential Synergistic Weight Loss: By hitting multiple targets (appetite, satiety, energy expenditure, and glucose metabolism) from different angles, the combination research has led to lead to more significant and sustained weight loss than either drug alone. The sum of their individual effects might be greater than the parts, as they could reinforce each other's mechanisms.
